Sequential immunosuppressive therapy in progressive IgA nephropathy

作者: Franz Maximilian Rasche , Frieder Keller , Lutz von Müller , David Czock , Philipp M. Lepper

DOI: 10.1159/000102313

关键词:

摘要: Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function proteinuria. We evaluated effect cyclophosphamide pulses (CyP) mycophenolic acid (MPA) sequential on patients with IgAN. Methods: Twenty IgAN advanced failure (median GFR 22 ml/min per 1.73m2) further disease activity (▿GFR -0.8 month) after (CyP; n = 18) or steroid pulse (n 2) were treated mycophenolate mofetil 1 g day for a median 27 months. Results: The monthly was significantly reduced linear regression analysis from -2.4 before CyP -0.12 CyP/MPA (p 0.0009). Estimated survival time prolonged by 65 months 0.0014). Proteinuria decreased 1.7 0.4 g/l during MPA treatment 0.015). In Cox analysis, only proteinuria g1.0g/l an independent risk factor doubling creatinine 0.03). Conclusion: A may arrest slow down reduces even who passed so called ‘point no return’

参考文章(20)
Karges W, Czock D, Sailer Lk, Keller F, von Müller L, Rasche Fm, Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy. Journal of Nephrology. ,vol. 19, pp. 465- ,(2006)
Tanenao Eto, Seiichiro Hara, Hiroyuki Komatsu, Yuji Sato, Shouichi Fujimoto, Satoshi Morita, Kazuhiro Yamada, "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR. Journal of Nephrology. ,vol. 18, pp. 690- 695 ,(2005)
G. D�Amico, A. Ragni, E. Gandini, G. Fellin, Typical and atypical natural history of IgA nephropathy in adult patients. Contributions To Nephrology. ,vol. 104, pp. 6- 13 ,(1993) , 10.1159/000422389
Dario Roccatello, Michela Ferro, Giulio Cesano, Daniela Rossi, Silvia Berutti, Mario Salomone, Giuseppe Piccoli, Luigi Massimino Sena, Steroid and cyclophosphamide in IgA nephropathy Nephrology Dialysis Transplantation. ,vol. 15, pp. 833- 835 ,(2000) , 10.1093/NDT/15.6.833
Mark Haas, Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases American Journal of Kidney Diseases. ,vol. 29, pp. 829- 842 ,(1997) , 10.1016/S0272-6386(97)90456-X
Bart D. Maes, Raymond Oyen, Kathleen Claes, Pieter Evenepoel, Dirk Kuypers, Johan Vanwalleghem, Boudewijn Van Damme, Yves F. Ch Vanrenterghem, Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney International. ,vol. 65, pp. 1842- 1849 ,(2004) , 10.1111/J.1523-1755.2004.00588.X
Sydney Tang, Joseph C.K. Leung, Loretta Y.Y. Chan, Y.U.N. H.O.I. Lui, Colin S.O. Tang, C.H.I. Hang Kan, Y.I.U. Wing Ho, K.A.R. Neng Lai, Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy Kidney International. ,vol. 68, pp. 802- 812 ,(2005) , 10.1111/J.1523-1755.2005.00460.X
Anthony C Allison, Elsie M Eugui, Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. ,vol. 47, pp. 85- 118 ,(2000) , 10.1016/S0162-3109(00)00188-0
M. ČOLIĆ, Z. STOJIĆ-VUKANIĆ, B. PAVLOVIĆ, D. JANDRIĆ, I. STEFANOSKA, Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells Clinical and Experimental Immunology. ,vol. 134, pp. 63- 69 ,(2003) , 10.1046/J.1365-2249.2003.02269.X